Imaging biomarkers in liver fibrosis

Area of Science:

• Hepatology and Medical Imaging
• Biomarker Discovery and Validation

Background:

• Chronic liver diseases (CLDs) are increasingly prevalent, leading to significant morbidity and mortality.
• Accurate staging of liver fibrosis is critical for determining patient prognosis and guiding therapeutic strategies.
• Liver biopsy, the traditional standard, has limitations including invasiveness and potential complications.

Purpose of the Study:

• To review non-invasive methods for in vivo quantification of liver fibrosis.
• To focus on biomarkers derived from Ultrasound and Magnetic Resonance imaging (MRI).
• To evaluate the diagnostic performance, clinical applicability, and value of these advanced techniques.

Main Methods:

• Review of current acquisition techniques for Ultrasound and MRI in fibrosis assessment.
• Analysis of various image processing methods applied to quantify liver fibrosis.
• Evaluation of diagnostic performance metrics and clinical utility of non-invasive biomarkers.

Main Results:

• Biomarker measurements from Ultrasound and MRI demonstrate high precision and reliability for fibrosis staging.
• These non-invasive methods offer a valuable alternative to liver biopsy.
• Understanding technique parameters, unit standardization, and quality control is essential for accurate interpretation.

Conclusions:

• Non-invasive biomarkers from Ultrasound and MRI are effective tools for evaluating liver fibrosis.
• These methods enhance the early identification and management of patients with chronic liver diseases.
• Standardization and quality control are vital for the reliable clinical application of these imaging techniques.